Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis
Primary result · Composite kidney function-related outcomeResult — go to the resultHazard ratio 0.75 95% CI 0.62–0.92Authors' conclusion
The estimated 25% reduced hazard of a kidney function-related outcome among participants assigned to DU highlights its potential for delaying or slowing the development of diabetic kidney disease in people with type 2 diabetes.
Study context
- Population
- People with T2D with previous CVD or cardiovascular risk factors (REWIND participants)
- Participants
- 4,949 vs 4,952
- Comparison
- Dulaglutide 1.5 mg vs placebo
- Dulaglutide (DU)n = 4,949
- Placebon = 4,952reference
- Primary endpoint
- Composite kidney function-related outcome:
- ≥40% sustained eGFR decline (CKD-EPI 2009)
- End-stage renal disease
- Renal-related death
Methodological detailsexploratory, intent-to-treat
- Exploratory
- Intent-to-treat
Primary result
Composite kidney function-related outcome
Hazard ratio
0.75
95% CI 0.62–0.92
P = 0.004
DUvs Placebo
HR 0.75 (95% CI 0.62–0.92); P = 0.004
As reported in the abstract
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| ≥40% sustained eGFR decline | 0.72 (0.58–0.88) | P = 0.002 | |
| 0.512Hazard ratio (log scale) |
Mean, mL/min/1.73 m²/year
| Outcome | DU | Placebo | P value |
|---|---|---|---|
| Mean annual eGFR slopeSmaller decline with DU | −1.37 | −1.56 | P < 0.001 |
Mean annual eGFR slope
- Results similar for all subgroups
Original publication
Dulaglutide and Kidney Function–Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diabetes Care. Published 21 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →